Epigenetic Mechanisms Underlying Melanoma Resistance to Immune and Targeted Therapies

Area of Science:

• Oncology
• Dermatology
• Cancer Biology

Background:

• Melanoma is an aggressive skin cancer with high mortality, even after primary tumor resection.
• Advances in targeted therapies (BRAF/MEK inhibitors) and immunotherapies (checkpoint blockade) have improved outcomes for metastatic melanoma.
• Therapy resistance, driven by genetic alterations and epigenetic reprogramming, remains a significant clinical challenge.

Purpose of the Study:

• To review the role of aberrant chromatin, transcriptional, and epigenetic regulation in melanoma therapy resistance.
• To discuss how targeting these epigenetic programs can overcome resistance to current melanoma treatments.

Main Methods:

• Literature review of studies on melanoma genetics, epigenetics, and therapy resistance.
• Analysis of the mechanisms by which epigenetic reprogramming contributes to cellular plasticity and treatment failure.
• Synthesis of evidence on targeting epigenetic pathways to enhance response to targeted and immune therapies.

Main Results:

• Epigenetic regulation of chromatin accessibility influences gene expression and distinct cell states in melanoma.
• Aberrant epigenetic modifications are emerging as key drivers of both intrinsic and acquired resistance to melanoma therapies.
• Targeting epigenetic regulators shows promise in resensitizing resistant melanoma cells.

Conclusions:

• Epigenetic reprogramming plays a critical role in melanoma's ability to resist targeted and immune therapies.
• Interventions aimed at modulating epigenetic landscapes offer a promising strategy to improve durable responses in melanoma patients.
• Further research into epigenetic mechanisms is crucial for developing next-generation melanoma treatments.